Eroxon-Maker Futura To Move Into Women’s Health Market

Successful study results, combined with encouraging market data, prompts Futura Medical to move forward with plans to commercialize a new OTC treatment for sexual dysfunction in women. To map out the path to a US launch, the firm has already held early discussions with the FDA.

(Shutterstock)

Futura Medical intends to follow up on its success with Eroxon by commercializing a non-prescription treatment for sexual dysfunction in women.

Reporting “positive results” from a study of its topical treatment WSD4000, UK-based Futura said development would continue apace with the goal of securing the necessary regulatory approvals to bring the product to market

More from Innovation & IP

More from Geography